This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (currently amended): A composition for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy ~~by tolerisation~~, the composition comprising an immunologically effective linear peptide fragment of a human platelet antigen (HPA) formulated for delivery through non-invasive routes.

Claim 2 (previously presented): The composition according to claim 1 wherein the condition is fetomaternal alloimmune response thrombocytopenia (FMAIT), post-transfusion purpura or platelet refractoriness.

Claim 3 (canceled)

Claim 4 (previously presented): The composition according to claim 3 wherein the HPA is selected from the group consisting of HPA-1a, HPA-1b, HPA-2a, HPA-2b, HPA-3a, HPA-3b, HPA-4a, HPA-4b, HPA-5a, HPA-5b, HPA-6a, HPA-6b, HPA-7a, HPA-7b, HPA-8a, HPA-8b, HPA-9a, HPA-9b, HPA-10a, HPA-10b, HPA-11a, and HPA-11b.

Claim 5 (previously presented): The composition according to claim 4 wherein the HPA has a genotype HPA-1a.

Claim 6 (previously presented): The composition according to claim 5 wherein the HPA-1a has sequence SEQ ID No:1, 2, 3, 4, 5, 6 or 7.

Claim 7 (previously presented): The composition according to claim 1 wherein the immunologically effective platelet protein or a peptide fragment thereof is formulated for delivery through mucosal tissue.

Claims 8-10 (canceled)

Claim 11 (currently amended): A method for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy ~~by tolerisation~~, the method comprising administering to a patient an immunologically effective linear peptide fragment of a human platelet antigen (HPA).

Claim 12 (previously presented): The method according to claim 11 wherein the condition is fetomaternal alloimmune response thrombocytopenia (FMAIT), post-transfusion purpura or platelet refractoriness.

Claim 13 (canceled)

Claim 14 (previously presented): The method according to claim 13 wherein the HPA is selected from the group consisting of HPA-1a, HPA-1b, HPA-2a, HPA-2b, HPA-3a, HPA-3b, HPA-4a, HPA-4b,

HPA-5a, HPA-5b, HPA-6a, HPA-6b, HPA-7a, HPA-7b, HPA-8a, HPA-8b, HPA-9a, HPA-9b, HPA-10a, HPA-10b, HPA-11a and HPA-11b.

Claim 15 (previously presented): The method according to claim 14 wherein the HPA has a genotype HPA-1a.

Claim 16 (previously presented): The method according to claim 15 wherein the HPA-1a has sequence SEQ ID No:1, 2, 3, 4, 5, 6 or 7.

Claim 17 (previously presented): The method according to claim 11 wherein the immunologically effective platelet protein or the peptide fragment thereof is formulated for delivery through mucosal tissue.

Claim 18 (new): A method for stimulating proliferation of peripheral blood mononuclear cells in a subject, said method comprising administering to the subject an immunologically effective linear peptide fragment of a human platelet antigen (HPA).